PCA
HALO icon

Providence Capital Advisors’s Halozyme HALO Stock Holding History

Providence Capital Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41
Closed -$2K – 364
2022
Q1 		$2K Buy
+41
New +$1.46K ﹤0.01% 363

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Providence Capital Advisors's HALO Position: Q2 2022 in Review

Providence Capital Advisors sold out of Halozyme (HALO) in Q2 2022, closing a stake of 41 shares — an estimated $2K sold.

Providence Capital Advisors first reported a position in HALO in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 367 funds tracked by Wall St. Rank hold HALO as of Q2 2022.

  • Providence Capital Advisors reported no remaining Halozyme position as of Q2 2022 after selling out during the quarter.
  • Providence Capital Advisors sold 41 Halozyme shares in Q2 2022, an estimated $2K.
  • Providence Capital Advisors first reported a position in Halozyme in Q1 2022 and held it in 1 quarter.
  • Providence Capital Advisors's Halozyme position peaked at $2K in Q1 2022.
  • 367 funds tracked by Wall St. Rank held Halozyme as of Q2 2022.

Based on Providence Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.